Drug Registration in Russia under EAEU Rules: Dossier Strategy, Quality Expertise and Market Authorization

Registration of a medicinal product in Russia is now part of the Eurasian Economic Union regulatory system. For a new application in 2026, the correct starting point is not the historical Russian national registration procedure but the EAEU Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use established by EEC Council Decision No. 78.

That change is more than terminology. It changes how the registration pathway is selected, how the dossier is built, how quality and clinical evidence are assessed, how GMP status is connected to the application, how Russia can later be linked to other EAEU markets, and how the product must be maintained after approval.

A registration project therefore should not start with translation of an existing global dossier. It should start with a regulatory decision:

Which EAEU pathway is appropriate for the intended market footprint, and is the existing dossier technically ready to survive the quality, safety and efficacy assessment in the chosen reference state?

For manufacturers entering Russia from China, India, Korea, MENA, CEE, Latin America or other non-EAEU markets, this is usually the highest-value decision in the project.

First decision: which EAEU registration pathway?

Decision No. 78 provides two core mechanisms for new registrations: mutual recognition and the decentralized procedure. Russia can act either as the reference state or as a recognition state, depending on the project.

Pathway 1 — Russia first, with Russia as the reference state

A manufacturer that initially needs access only to the Russian market can register the product in Russia as the reference state under the EAEU mutual-recognition framework. Decision No. 78 formally describes this as registration in the reference state for circulation only in that state.

This is not a return to the old Russian national dossier. The dossier and expert assessment are conducted under EAEU requirements.

After approval in Russia, the same EAEU registration can later be expanded into one or several other EAEU member states through the mutual-recognition procedure. The Russian expert assessment report then becomes the regulatory basis for the recognition-state review.

This route can be attractive where Russia is the immediate commercial priority and launches in Belarus, Kazakhstan, Armenia or Kyrgyzstan are planned later.

Pathway 2 — simultaneous entry into Russia and other EAEU markets

If the commercial plan requires several EAEU countries from the beginning, a decentralized procedure may be more appropriate. The applicant selects one reference state and one or more recognition states and runs the assessment in a coordinated procedure.

Russia may be selected as the reference state or as one of the recognition states.

The important point is that only one state can be the reference state. That state carries the primary scientific assessment and prepares the assessment report used by the other participating states.

Pathway 3 — Russia as a recognition state after EAEU registration elsewhere

If the medicinal product is already registered under the EAEU Rules in another member state acting as the reference state, Russia can be added through mutual recognition.

In that case, the strategic question is no longer how to recreate a Russian registration dossier. It is whether the current EAEU dossier, assessment report, product information, quality document and post-approval history are sufficiently harmonized and current for recognition in Russia.

The pathway is a lifecycle decision, not only a filing decision

Choosing the reference state affects more than the first approval date.

The reference state remains central to the future regulatory history of the product: assessment reports, many lifecycle procedures, recognition-state expansion and coordination of changes all depend on the integrity of the reference-state dossier.

For that reason, Pharegis evaluates the pathway against the expected five- to ten-year product strategy, not only against the first submission.

Questions include:

• Is Russia the first and dominant EAEU market, or one of several simultaneous launch markets?
• Will additional recognition states probably be added within the first two years?
• Is the dossier likely to require major CMC changes while mutual recognition is still being expanded?
• Which manufacturing sites and GMP certificates will support the portfolio?
• Are product information, pack configurations and trade-name strategy compatible across the intended states?
• Which authority should logically hold the primary assessment history for the product?

Current Decision No. 78 also contains mechanisms for handling certain variations in the reference state before or during expansion to recognition states. That flexibility makes document-version control even more important: an outdated expert report, quality document or product-information sequence can create avoidable divergence between states.

The official 140-working-day reference-state clock is not the complete project timeline

For initial registration under the mutual-recognition procedure (MRP) in the reference state, paragraph 46 of Decision No. 78 sets a maximum duration of 140 working days from submission of the registration application to issuance of the marketing authorization, excluding applicant clock-stops and other periods specifically excluded by the Rules.

This 140-working-day limit is not a 2025 change. It was introduced by EEC Council Decision No. 36 of 17 March 2022, effective from 28 March 2022, replacing the previous 210-calendar-day framework. The 2022 amendment was part of a broader optimization of EAEU registration and expert-review procedures.

The subsequent mutual-recognition stage in a recognition state is separate from the 140-working-day reference-state registration. Under the current Rules, the recognition-state expert review is conducted within 40 working days from receipt of access to the current assessment report. For the decentralized procedure (DCP), the overall duration must not exceed 140 working days in the reference state and 50 working days in each participating recognition state.

Those regulatory limits should not be used as a promise of launch timing.

The real project starts months earlier and includes:

product qualification → pathway decision → dossier gap assessment → CMC remediation → evidence strategy → GMP readiness → Russian/local Module 1 preparation → electronic dossier assembly → sample/reference-standard readiness → filing → validation → expert review → laboratory testing → responses to questions → product-information finalization → authorization.

For requests issued during the reference-state procedure, the applicant normally has no more than 90 working days from receipt of the request to submit the response. On a justified request from the applicant, the competent authority or expert organization may extend that period; however, the total time allowed for responses to requests must not exceed 180 working days. In practical terms this can provide up to a further 90 working days, but the extension is not automatic and must be justified and granted. Applicant response time is excluded from the registration/expertise clock. Under the current consolidated Rules, assessment of the submitted response is performed within no more than 5 working days and is also excluded from the registration/expertise timeline.

A technically weak dossier can therefore remain “inside a 140-working-day procedure” while the actual calendar time expands substantially.

The best timeline optimization is usually performed before filing, not after the first deficiency letter.

Dossier qualification comes before dossier writing

A registration dossier is not simply “CTD Modules 1–5”. Its evidence requirements depend on what type of application is being made.

Before document production begins, the product should be correctly qualified—for example as an original medicinal product, generic, hybrid, biosimilar, well-established-use product or another applicable category under the EAEU framework.

The classification affects the content expected in Modules 4 and 5 and the evidence needed to bridge the proposed product to existing knowledge.

For a generic product, the central question may be bioequivalence or an applicable biowaiver. For a hybrid product, additional nonclinical and/or clinical evidence may be necessary because a simple generic bridge is not sufficient. A biosimilar requires a structured comparability programme against an appropriate reference biological product. An original product requires a complete evidence package appropriate to its development programme.

This is why “Do we need a local Russian clinical trial?” is the wrong first question.

There is no universal EAEU rule requiring every foreign medicinal product to repeat a clinical programme in Russia. The correct question is whether the available quality, nonclinical and clinical evidence satisfies the EAEU requirements for the specific product and application type.

The historical Russian concept of obligatory local registration trials should not be used as a planning assumption for new EAEU registrations.

The dossier is electronic CTD, but the regulatory work is not document formatting

Decision No. 78 requires the registration dossier in the Common Technical Document structure:

• Module 1 — administrative and region-specific information;
• Module 2 — quality, nonclinical and clinical summaries and overviews;
• Module 3 — quality / CMC;
• Module 4 — nonclinical study reports;
• Module 5 — clinical study reports.

The EAEU framework supports electronic submission and maintains technical requirements for the electronic registration dossier and information exchange between member states.

The difficult part is not creating the folders. It is ensuring that every module describes the same medicinal product.

A change made in Module 3 may affect the quality overall summary, the quality document, stability commitments, GMP scope, analytical sample package or a manufacturing-site variation. A change in clinical positioning may affect the SmPC, package leaflet, risk-management plan and labeling. A deficiency response can therefore touch several dossier modules at once.

Pharegis manages the dossier as a controlled regulatory dataset rather than a collection of independently edited documents.

CMC is often the longest pre-submission workstream

For many established products manufactured outside the EAEU, the largest gap is not efficacy or safety. It is the difference between the manufacturer’s global CMC package and the dossier expected for EAEU expert assessment.

Module 3 should be reviewed at the level of manufacturing reality and analytical evidence, including where relevant:

• active-substance manufacturer and control strategy;
• manufacturing process and process controls;
• specifications and impurity strategy;
• analytical procedures and validation/verification;
• reference standards and materials;
• excipient controls;
• pharmaceutical development;
• finished-product manufacturing process;
• in-process controls;
• process validation or verification;
• finished-product release and shelf-life specifications;
• packaging system;
• stability data and commitments;
• manufacturing, packaging and testing sites.

The EAEU quality document and the specifications used during expert assessment must be consistent with the underlying CTD and with the methods the expert laboratory is expected to reproduce.

This is not a translation exercise.

A specification developed for the US, EU, Chinese or Indian market may use different pharmacopoeial references, test logic, acceptance criteria or analytical conventions. The EAEU Pharmacopoeia is a living regulatory source, and Russian-market projects also require awareness of the current State Pharmacopoeia of the Russian Federation where relevant to the national execution of quality control.

Pharegis therefore performs a CMC/pharmacopoeial gap review before finalizing the quality document and submission package.

3.2.P.5, the quality document and laboratory reproducibility must tell the same story

For the finished medicinal product, CTD section 3.2.P.5 — Control of Drug Product is one of the core expert-review interfaces. It contains the specifications, analytical procedures, method validation information, batch analyses and justification of specifications that support routine quality control.

The EAEU Rules require detailed release and shelf-life specifications, justification of quality attributes, analytical procedures and validation. If the primary packaging itself functions as an administration device, current Decision No. 78 also contains additional requirements for relevant functional testing and package-related evidence.

The project should therefore reconcile:

3.2.P.5 → quality overall summary → approved quality document → laboratory test package → future commercial QC practice.

A method that is scientifically acceptable but cannot be reproduced by the expert laboratory without undocumented equipment, software, columns, reference materials or calculation conventions is a registration risk.

Samples, standards and laboratory expertise are part of the critical path

Decision No. 78 provides for laboratory testing of medicinal-product samples against the quality document and assessment of reproducibility of the proposed quality-control methods in accredited testing laboratories.

Samples, API reference standards, related-impurity standards, specific reagents and other materials are provided in coordination with the expert organization. The current wording of Decision No. 78 is important here: quantities are agreed with the expert organization and must be sufficient for no more than a threefold analysis under the applicable quality document or dossier specifications. The Rule therefore does not say “at least three analyses”; the exact quantity is determined with the expert organization against the actual testing programme.

This means the laboratory workstream has to begin before submission.

For an imported product, Pharegis maps:

• sample quantity and batch selection;
• certificates of analysis;
• API and impurity reference standards;
• special reagents, columns or consumables;
• storage and transportation conditions;
• import/customs documentation where required;
• analytical method transfer risks;
• any test that may be difficult to reproduce in the expert laboratory.

Decision No. 78 also provides alternative arrangements for certain products or methods that cannot reasonably be tested in the expert laboratory, including testing in the manufacturer’s or contract laboratory in the presence of representatives of the expert organization in applicable cases.

The key point is operational: registration quality expertise is a physical laboratory event, not only a review of PDF files.

EAEU GMP has to be synchronized with the dossier

For foreign manufacturing sites, EAEU GMP compliance should be mapped at the same time as the registration dossier.

The applicable manufacturing standard is the EAEU GMP Rules under Decision No. 77, with pharmaceutical inspections conducted under Decision No. 83. The relevant site, dosage forms and manufacturing operations have to match the manufacturing chain presented in the dossier.

A global GMP certificate, EU inspection history, PIC/S inspection or national license may be valuable background evidence, but it should not be assumed to replace the EAEU GMP workstream required for the product.

Pharegis therefore connects three maps:

dossier manufacturing chain → EAEU GMP certificate/inspection scope → target registration timeline.

If a required site does not yet have the necessary EAEU GMP position, inspection readiness becomes part of the registration critical path rather than a parallel administrative task.

Clinical and nonclinical evidence: assess the EAEU requirement, not an old Russian myth

The old Russian registration model is still widely repeated online: foreign manufacturers are told that local clinical studies are automatically required for registration in Russia.

That is an outdated basis for planning a new application under the EAEU Rules.

Decision No. 78 evaluates the evidence appropriate to the application type. For example:

• a generic medicinal product normally relies on pharmaceutical equivalence and bioequivalence evidence where required, or a justified biowaiver where permitted;
• a hybrid application may require additional nonclinical and/or clinical data;
• a biosimilar requires comparative quality, nonclinical and clinical evidence according to the applicable EAEU biological-product framework;
• an original medicinal product requires a complete development package appropriate to the claimed indications and benefit-risk profile.

The regulatory task is to determine whether the manufacturer’s existing global development programme is acceptable under the EAEU framework and where a real evidence gap exists.

Pharegis does not recommend a study because it is “traditionally done in Russia”. A study should be initiated because the applicable EAEU rule, product characteristics or existing data require it.

Russia-specific localization still matters

Union rules harmonize the scientific dossier, but a Russian market authorization still has country-specific execution requirements.

Module 1, the application, product information, packaging and administrative documents have to be prepared for the Russian procedure. The Russian-language SmPC, package leaflet and labeling must remain technically consistent with the scientific claims and quality configuration approved in the dossier.

This is particularly sensitive where source documents have evolved independently in several markets.

Translation should therefore be controlled as regulatory authoring. A change in indication, contraindication, dosing, storage condition, manufacturing site, shelf life or pack configuration must not be introduced accidentally during localization.

The same principle applies when Russia is a recognition state: local product information must be aligned to the approved reference-state dossier rather than recreated as a separate national product.

Expert questions should be answered across the dossier, not document by document

A deficiency letter is often treated as a list of separate questions. That is risky.

One CMC question can affect the quality overall summary, Module 3, the quality document, sample testing and GMP scope. One clinical question can affect Module 2, Module 5, the SmPC, package leaflet and risk-management plan.

Pharegis manages expert questions through an impact matrix:

question → underlying issue → affected dossier sections → affected approved texts → evidence owner → response → consequential change.

The purpose is to avoid “solving” a question in one document while creating a contradiction elsewhere.

This approach is especially important during mutual-recognition expansion, where the reference-state assessment report and the dossier sequence must stay synchronized for the recognition states.

Where registration projects most often lose time

The recurring causes of delay are usually visible before filing:

• selecting the pathway only after the dossier has already been localized;
• filing a global CTD without qualifying the EAEU application type;
• relying on an outdated Module 3 that no longer reflects commercial manufacturing;
• preparing the quality document before completing the pharmacopoeial and analytical gap assessment;
• starting the EAEU GMP workstream too late;
• discovering after validation that samples, impurity standards or special reagents are not shipment-ready;
• assuming a foreign clinical package automatically meets EAEU requirements—or assuming a Russian local study is automatically required;
• treating Russian SmPC, leaflet and labeling as translation-only deliverables;
• responding to expert questions without cross-dossier impact control;
• introducing manufacturing or specification changes during the procedure without version-control strategy;
• planning only for first approval and ignoring later recognition states, variations and renewal.

The common feature is not regulatory complexity itself. It is failure to place the dependencies on one critical path.

Approval is the beginning of the EAEU lifecycle

A first marketing authorization in the reference state is generally issued for five years. Subject to successful confirmation of registration, an indefinite marketing authorization can then be issued, except where the authority determines that another limited term is appropriate for pharmacovigilance or other reasons provided by the Rules.

Before that renewal point, the product may already accumulate variations, manufacturing changes, safety updates, new pack configurations, additional recognition states or supply-chain changes.

For that reason, the dossier should be built from the beginning as the regulatory baseline for lifecycle management.

A registration strategy that obtains approval quickly but creates an unmaintainable Module 3, fragmented product information or an incomplete GMP scope is not an efficient strategy.

What Pharegis manages in a Russia/EAEU registration project

Pharegis can manage a defined regulatory workstream or act as the external regulatory function for the complete Russia/EAEU market-entry programme. Typical deliverables include:

• EAEU pathway memo — Russia as reference state, decentralized procedure, or Russia as recognition state;
• application-type qualification and evidence strategy;
• dossier gap matrix across Modules 1–5;
• critical-path plan integrating dossier, evidence, GMP, samples and submission;
• CMC review and Module 3 remediation plan;
• pharmacopoeial gap assessment and quality-document strategy;
• review of 3.2.P.5 and analytical-method reproducibility risks;
• sample, reference-standard and laboratory-testing plan;
• coordination of EAEU GMP inspection/certificate dependencies;
• Russian Module 1 and administrative package;
• regulatory localization of SmPC, package leaflet and labeling;
• electronic dossier assembly/version control;
• submission and authority communication;
• expert-question impact assessment and response coordination;
• recognition-state expansion after Russian approval;
• variation and lifecycle planning after authorization.

For a mid-size manufacturer without an EAEU regulatory department, these workstreams can be managed as one outsourced market-entry function. For a multinational pharmaceutical company, Pharegis can take responsibility for a defined high-complexity segment—CMC remediation, Russian recognition, expert responses, GMP dependency, dossier recovery or lifecycle restructuring—without duplicating the client’s global regulatory organization.

Discuss a Russia / EAEU registration project

The most useful first discussion happens before translation and submission work begins.

For an initial assessment, prepare:

• product name, dosage form, strength and intended indications;
• intended EAEU markets and desired launch sequence;
• current registration status in other countries;
• current CTD/eCTD or equivalent dossier;
• application type proposed by the manufacturer;
• manufacturing-site list and current GMP status;
• API and finished-product specifications;
• available bioequivalence, nonclinical and clinical evidence;
• target filing and launch dates;
• known planned manufacturing or CMC changes within the next 12–24 months.

Pharegis can then determine the appropriate EAEU pathway, identify the evidence and CMC gaps, place GMP and laboratory work on the same critical path and define which issues should be corrected before the formal regulatory clock starts.

The objective is not merely to submit a dossier in Russia. It is to establish an EAEU registration that can be approved, expanded to other markets and maintained through the product lifecycle.

Regulatory basis

• EEC Council Decision No. 78 of 3 November 2016 — Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use, consolidated version including amendments through Decision No. 93 of 26 November 2025.
• EEC Council Decision No. 36 of 17 March 2022 — amendment that introduced the 140-working-day reference-state registration limit and optimized MRP/DCP timelines.
• EEC Council Decision No. 77 of 3 November 2016 — Good Manufacturing Practice Rules of the Eurasian Economic Union.
• EEC Council Decision No. 83 of 3 November 2016 — Rules for Pharmaceutical Inspections.
• EAEU requirements and technical documents for electronic medicinal-product registration dossiers and integrated information exchange.
• Pharmacopoeia of the Eurasian Economic Union and applicable current pharmacopoeial requirements.

Regulatory status reviewed: August 2026.